Indium (111In) imciromab is a monoclonal antibody (mAb) targeting the extracellular domain of the human epidermal growth factor receptor 2 (HER2). It is labeled with the radioisotope indium-111 (111In) and is used in nuclear medicine imaging to detect HER2-expressing tumors. 111In imciromab is a promising agent for imaging of HER2-expressing cancers, including breast, gastric, and colorectal cancer. It has been used in research studies to detect HER2-expressing tumors in humans, as well as to assess the efficacy of treatments targeting HER2-expressing tumors.
Indium (111In) imciromab, similar to Indium (111In) capromab pendetide, belonged to a class of radiopharmaceutical agents used for diagnostic imaging. However, it shares the same fate: no longer commercially available and not employed in current medical practice.
Here's a summary of its characteristics:
Function:
- Aimed to diagnose and image tumors, particularly neuroendocrine tumors.
- Imciromab: This component functioned as a monoclonal antibody specifically targeting a protein called carcinoembryonic antigen (CEA), present in various tumor types, including neuroendocrine tumors.
- Indium-111 (111In): Attached to imciromab, this radioactive isotope allowed for detection through single-photon emission computed tomography (SPECT) imaging.
Applications:
- Historical use: In the past, Indium (111In) imciromab was used to:
- Visualize the location and extent of neuroendocrine tumors.
- Aid in treatment planning by identifying potential areas for surgery or radiotherapy.
Reasons for discontinuation:
- Limited specificity: Imciromab couldn't solely distinguish between cancerous and non-cancerous tissues, as CEA can also be present in some benign conditions.
- Advancements in diagnostic techniques: Similar to Indium (111In) capromab pendetide, the development of more accurate and reliable imaging methods like Gallium-68 (Ga-68) DOTATATE PET scans and Fluorodihydroxyphenylalanine (FDOPA) PET scans using different radiotracers rendered Indium (111In) imciromab obsolete.
Current Status:
- Not in clinical use: Due to the limitations mentioned earlier, Indium (111In) imciromab is no longer commercially available and not recommended for routine clinical practice.
Important Note:
- Outdated information: Resources referring to Indium (111In) imciromab might be outdated and should not be considered the primary source of information for diagnosing or managing neuroendocrine tumors.
Alternative diagnostic methods:
- Ga-68 DOTATATE PET scans: This imaging technique utilizes a radiotracer (Ga-68 DOTATATE) that specifically targets a receptor protein abundant in neuroendocrine tumors, providing a more precise diagnosis.
- FDOPA PET scans: These scans employ a different radiotracer (FDOPA) to assess the activity of tumor cells, aiding in tumor detection and treatment planning.
Disclaimer:
- I am not a medical professional and cannot provide medical advice.
- The information provided here is for educational purposes only and should not be interpreted as a substitute for professional medical consultation.
- Always consult with a qualified healthcare provider for diagnosis, treatment, and the latest advancements in managing neuroendocrine tumors.